Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity

Obesity Research

Volumn 11, Issue 9, 2003, Pages 1147-1154

  Kok, Simon W ^a   Overeem, Sebastiaan ^a   Visscher, Tommy L S ^b   Lammers, Gert Jan ^a   Seidell, Jaap C ^b   Pijl, Hanno ^a   Meinders, Arend E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Body fat; Body weight; Narcolepsy; Orexin; Waist circumference

Indexed keywords

CARRIER PROTEIN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ABDOMEN; ADULT; AGED; ARTICLE; BLOOD; BODY CONSTITUTION; BODY MASS; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; FEMALE; HISTOLOGY; HUMAN; MALE; MIDDLE AGED; NARCOLEPSY; OBESITY; PREVALENCE; SOMNOLENCE;

ABDOMEN; ADULT; AGED; AGED, 80 AND OVER; BODY CONSTITUTION; BODY MASS INDEX; CARRIER PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERSOMNOLENCE, IDIOPATHIC; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPEPTIDES; OBESITY; PREVALENCE;

EID: 1542705308     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2003.156     Document Type: Article

References (51)

1. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50:S16-S22.
2. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437-51.
3. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-76.
4. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39-40.
5. Cave HA. Narcolepsy. Arch Neurol Psychiatr. 1931;26:50-101.
6. Daniels LE. Narcolepsy. Medicine. 1934;13:1-122.
7. Roth B. Narkolepsie und Hypersomnie. Berlin: VEB Verlag Volk und Gesundheit; 1962.
8. Bell IR. Diet histories in Narcolepsy. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976, pp. 221-8.
9. Kotagal S, Hartse KM, Walsh JK. Characteristics of narcolepsy in preteenaged children. Pediatrics. 1990;85:205-9.
10. Allsopp MR, Zaiwalla Z. Narcolepsy. Arch Dis Child. 1992;67:302-6.
11. Dahl RE, Holttum J, Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry. 1994;33:834-41.
12. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet. 2000;355:1274-5.
13. Dahmen N, Bierbrauer J, Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci. 2001;251:85-9.
14. Björntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 1997;13:795-803.
15. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097-105.
16. Narbro K, Jonsson E, Larsson B, Waaler H, Wedel H, Sjöström L. Economic consequences of sick-leave and early retirement in obese Swedish women. Int J Obes Relat Metab Disord. 1996;20:895-903.
17. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.
18. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345-54.
19. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-85.
20. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci. 2001;24:429-58.
21. Bassetti C, Gugger M, Mathis J, et al. Cerebrospinal fluid levels of hypocretin (orexin) in hypersomnolent patients without cataplexy. Actas de Fisiologia. 2001;7:205.
22. Kanbayashi T, Yano T, Ishiguro H, et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep. 2002;25:337-9.
23. International Classification of Sleep Disorders. International Classification of Sleep Disorders: Diagnostic and Coding Manual, Revised. Rochester, MN: American Sleep Disorders Association; 1997.
24. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18:78-105.
25. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553-62.
26. Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Educational level, relative body weight, and changes in their association over 10 years: an international perspective from the WHO MONICA Project. Am J Public Health. 2000;90:1260-8.
27. Seidell JC. Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr. 2000;83(Suppl 1):S5-S8.
28. Douglas NJ. The psychosocial aspects of narcolepsy. Neurology. 1998;50(Suppl. 1):S27-S30.
29. Goswami M. The influence of clinical symptoms on quality of life in patients with narcolepsy. Neurology. 1998;50(Suppl. 1):S31-S36.
30. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-61.
31. Nawaz H, Chan W, Abdulrahman M, Larson D, Katz DL. Self-reported weight and height: implications for obesity research. Am J Prev Med. 2001;20:294-8.
32. Palta M, Prineas RJ, Berman R, Hannan P. Comparison of self-reported and measured height and weight. Am J Epidemiol. 1982;115:223-30.
33. Seidell JC, Bouchard C. Abdominal adiposity and risk of heart disease. JAMA. 1999;281:2284-5.
34. Segal KR, Dunaif A, Gutin B, Albu J, Nyman A, Pi-Sunyer FX. Body composition, not body weight, is related to cardiovascular disease risk factors and sex hormone levels in men. J Clin Invest. 1987;80:1050-5.
35. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord. 2001;25:1047-56.
36. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet. 1998;351:853-6.
37. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord. 2001;25:1183-8.
38. Dobbelsteyn CJ, Joffres MR, MacLean DR, Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. Int J Obes Relat Metab Disord. 2001;25:652-61.
39. Seidell JC, Visscher TL. Body weight and weight change and their health implications for the elderly. Eur J Clin Nutr. 2000;54(Suppl 3):S33-S39.
40. Honda Y, Doi Y, Ninomiya R, Ninomiya C. Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep. 1986;9:254-9.
41. Seidell JC, Kahn HS, Williamson DF, Lissner L, Valdez R. Report from a Centers for Disease Control and Prevention Workshop on use of adult anthropometry for public health and primary health care. Am J Clin Nutr. 2001;73:123-6.
42. Broughton R, Dunham W, Newman J, Lutley K, Duschesne P, Rivers M. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol. 1988;70:473-81.
43. Middelkoop HA, Lammers GJ, Van Hilten BJ, Ruwhof C, Pijl H, Kamphuisen HA. Circadian distribution of motor activity and immobility in narcolepsy: assessment with continuous motor activity monitoring. Psychophysiology. 1995;32:286-91.
44. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(Suppl. B):S55-S87.
45. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf. 1996;14:329-42.
46. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord. 1984;7:133-8.
47. Yamada H, Okumura T, Motomura W, Kobayashi Y, Kongo Y. Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. Biochem Biophys Res Commun. 2000;267:527-31.
48. Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept. 2002;104:153-9.
49. Lammers GJ, Pijl H, Iestra J, Langius JA, Buunk G, Meinders AE. Spontaneous food choice in narcolepsy. Sleep. 1996;19:75-6.
50. Peyron C, Charnay Y. Hypocretin (orexin) and narcolepsy. J Steep Res. 2002;11:260.
51. Chou TC, Lee CE, Lu J, et al. Orexin (hypocretin) neurons contain dynorphin. J Neurosci. 2001;21:RC168:1-6.